Field Trip will make its trading debut on Tuesday.
Field Trip will make its trading debut on Tuesday.
This is MindMed's first step in establishing a Center for Psychedelic Medicine at NYU Langone Health.
Field Trip Psychedelics is targeting a $16 billion treatment market with its ketamine-assisted psychotherapy clinics.
Field Trip to commence trading October 7th on the CSE, symbol "FTRP".
Dr. Dan Engle, a leading voice in psychedelic medicine, has been appointed by Mind Cure (CSE:MCUR) as a scientific advisor
The world-renowned transformative medicine expert will contribute towards Mind Cure's work in the realm of psychedelic research, treatment and integration
Field Trip announces testing of its first synthesized psychedelics molecule.
Mind Cure's new Chief Operating Officer has already launched several successful businesses.
The company bolsters its executive team with the addition of an industry leader and experienced entrepreneur
With trading volumes going through the roof and a potential NASDAQ listing, will MindMed be the next billion-dollar psychedelics company?
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now